6. Paediatric populations.
| Trial | Omalizumab | Placebo | % |
| Bardelas 2012 | Footnote1 | ||
| Busse 2001 | 20/268 | 21/257 | 7.8% |
| Busse 2011 | Footnote2 | ||
| Hanania 2011 | 23/427 | 16/421 | 4.6% |
| Holgate 2004 and Holgate 2004a (N between 12 and 17 years) | 12/176 | 9/165 | 6.5% |
| Lanier 2009 | 421/421 | 206/206 | 100% |
| Milgrom 2001 | 225/225 | 109/109 | 100% |
| NCT00096954 | Footnote3 | ||
| Solèr 2001 | 18/274 | 17/272 | 6.4% |
1Bardelas 2012 included participants from 12 years of age. However, no details are provided in the study report on the proportion of paediatric participants in the sample (mean ages: omalizumab 41.9 ± 14.60 and placebo 40.7 ± 14.85).
2Busse 2011 included participants from six to 20 years of age. However, no details are provided in the study report on the proportion of paediatric participants in the sample (mean ages: omalizumab 10.8 ± 3.4 and placebo 10.9 ± 3.6).
3NCT00096954 included participants from 12 years of age. However, no details are provided in the study report on the proportion of paediatric participants in the sample (mean ages: omalizumab 36.0 ± 14.7 and placebo 38.1 ± 15.1).